OVERVIEW
Salivary tests are available for a number of hormones. Salivary hormone tests include but are not limited to estrogens, progesterone, testosterone, melatonin, cortisol, and dehydroepiandrosterone (DHEA). A number of salivary tests are available to consumers over the Internet without a physician's prescription. The results of these tests are purportedly used to determine the need for prescriptions for different hormones, vitamins, and herbs that are said to help in the management of menopause and aging.

MEDICAL CRITERIA
None

PRIOR AUTHORIZATION
Not applicable

POLICY STATEMENT
BlueCHiP for Medicare and Commercial Products
The use of salivary hormone testing is considered not medically necessary as there is insufficient peer-reviewed scientific literature that demonstrates that the procedure/service is effective.

COVERAGE
Benefits may vary between groups and contracts. Please refer to the appropriate Benefit Booklet, Evidence of Coverage, or Subscriber Agreement for applicable Not Medically Necessary benefits/coverage.

BACKGROUND
Salivary Testing for Management of Menopause and/or Aging
The scientific validity of salivary hormone levels in order to diagnose or monitor hormone deficiency has not been established. There are no published studies that document the validity of using salivary hormone testing to diagnose, treat, or monitor menopause or aging. The American College of Obstetricians and Gynecologists (ACOG), the U.S. Food and Drug Administration (FDA), the North American Menopause Society (NAMS), the Institute for Clinical Systems Improvement, and the American Association of Clinical Endocrinologists (AACE) have all issued statements that address the questionable validity of salivary hormone testing:

- ACOG's Committee Opinion #322, *Compounded Biodentical Hormones*, indicates that salivary hormone testing is not meaningful because salivary hormone levels vary within each woman depending on her diet, the time of day, the specific hormone being tested, and other variables (ACOG 2005).
- The FDA states that "there is no scientific basis for using salivary testing to adjust hormone levels." 
- NAMS indicates in their July 2008 Position Statement: *Estrogen and progestogen use in postmenopausal women* "salivary hormone testing is a procedure that has not been proven accurate or reliable." (NAMS 2008)
- The Institute for Clinical Systems Improvement concluded in its 2008 assessment: "Currently, there is insufficient evidence in the published scientific literature to permit conclusions concerning the use of salivary hormone testing for the diagnosis, treatment, or monitoring of menopause and aging." (ICSI 2008)
- The AACE’s Reproductive Medicine Committee 2007 Position Statement on Bioidential Hormones states "individualized dosing frequently based upon unproven testing methods such as salivary assays, which has not been validated."
Salivary Testing for Preterm Birth

Preterm birth is considered a major healthcare problem worldwide. The National Center for Health Statistics reports that approximately 11% of the estimated 4 million births in the United States annually are preterm, incurring significant morbidity and mortality. Therefore, identification of women at risk for preterm labor has been a research focus for many years, with the hope that early intervention can prevent the progression from preterm labor to preterm birth. Current techniques include a scoring system based on a patient’s past medical history (the Creasy system), home uterine activity monitoring, and measurements of fetal fibronectin collected on a cervical swab. It has also been observed that salivary estriol levels surge several weeks before the onset of spontaneous preterm labor. Therefore, measurement of salivary estriol has been explored as a risk predictor for preterm labor. SalEst™ is a laboratory technique approved by the FDA for measuring salivary estriol as a risk assessment marker of preterm labor and delivery. The SalEst system is indicated for use every 1 to 2 weeks in pregnant women with singleton pregnancies between their 22nd and 36th weeks of pregnancy.

No clinical studies are available that demonstrate that treatment decisions based on salivary testing result in beneficial health outcomes, therefore Salivary Testing is considered not medically necessary as there is no proven efficacy.

COVERAGE
Benefits may vary between groups and contracts. Please refer to the appropriate Evidence of Coverage or Subscriber Agreement for the applicable Services Not Medically Necessary benefits/coverage.

CODING
BlueCHiP for Medicare and Commercial Products
The following HCPCS codes are considered not medically necessary:
S3650 Saliva test, hormone level; during menopause
S3652 Saliva test, hormone level; to assess preterm labor risk

RELATED POLICIES
None

PUBLISHED
Provider Update, June 2016
Provider Update, December 2015
Provider Update, January 2015
Provider Update, October 2013
Provider Update, September 2012
Provider Update, July 2011
Provider Update, December 2010
Provider Update, July 2009
Provider Update, June 2008

REFERENCES
http://www.menopause.org/publications/clinical-practice-materials/bioidentical-hormone-therapy/what-is-hormone-testing-

5. American Association of Clinical Endocrinologists (AACE) Reproductive Medicine Committee Position Statement on Bioidentical Hormones

This medical policy is made available to you for informational purposes only. It is not a guarantee of payment or a substitute for your medical judgment in the treatment of your patients. Benefits and eligibility are determined by the member’s subscriber agreement or member certificate and/or the employer agreement, and those documents will supersede the provisions of this medical policy. For information on member-specific benefits, call the provider call center. If you provide services to a member which are determined to not be medically necessary (or in some cases medically necessary services which are non-covered benefits), you may not charge the member for the services unless you have informed the member and they have agreed in writing in advance to continue with the treatment at their own expense. Please refer to your participation agreement(s) for the applicable provisions. This policy is current at the time of publication; however, medical practices, technology, and knowledge are constantly changing. BCBSRI reserves the right to review and revise this policy for any reason and at any time, with or without notice. Blue Cross & Blue Shield of Rhode Island is an independent licensee of the Blue Cross and Blue Shield Association.